WBA - Jeff Bezos Vs. Elon Musk Space Contract Lawsuit Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations Tesla Rival XPeng's August Deliveries Zooms 43%: Today's Top Stories | Benzinga
Tech Crunch
Jeff Bezos Vs. Elon Musk: Feud Takes Center Stage in Amazon's Space Contract Lawsuit
- An institutional investor prosecuted Amazon.Com Inc (NASDAQ: AMZN) and its board, including Jeff Bezos, over launch contracts awarded to Bezos' space company, Blue Origin.
- Amazon shareholders, the Cleveland Bakers and Teamsters Pension Fund, claim that Amazon's board quickly approved the launch agreements for Project Kuiper without considering competitor SpaceX.
- Project Kuiper is Amazon's constellation of 3,236 low-Earth satellites to blanket the globe, versus Elon Musk-led SpaceX's Starlink broadband mega constellation.
Google Removes Controversial Video Chat App Chamet from Play Store
- Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google booted out the live video chat app Chamet from the Play Store, citing violations of its user-generated content (UGC) policy. The app, which lets users call stream hosts with payments privately, was pulled from the Play Store in August.
- The decision to remove Chamet comes from Google's policy to remove apps that primarily feature objectionable UGC. Although Chamet had warnings against broadcasting certain content, it contained suggestive material and ads.
CNBC
Novo Nordisk's Famed Drug Ozempic Could Be Contender For Medicare Negotiations
- Novo Nordisk A/S's (NYSE: NVO) Ozempic, the highly sought-after diabetes treatment, may soon enter the realm of price negotiations between drug manufacturers and Medicare.
- Ozempic is poised to become eligible for negotiations when the next batch of drugs is chosen in 2025, leading to price adjustments taking effect in 2027.
- This spending amount is comparable to some of the medications currently under consideration for price discussions this week, out of a total Part D expenditure of $98 billion in 2021.
Financial Times
Inflection AI's CEO Wants Restrictions on Nvidia Chip Sales: The Ethical Debate
- Mustafa Suleyman, the CEO of Inflection AI and co-founder of DeepMind, believes that Washington should impose restrictions on the sale of Nvidia Corp (NASDAQ: NVDA) chips, vital components ...